WO2008016258A1 - Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same - Google Patents
Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same Download PDFInfo
- Publication number
- WO2008016258A1 WO2008016258A1 PCT/KR2007/003699 KR2007003699W WO2008016258A1 WO 2008016258 A1 WO2008016258 A1 WO 2008016258A1 KR 2007003699 W KR2007003699 W KR 2007003699W WO 2008016258 A1 WO2008016258 A1 WO 2008016258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanoliposome
- lecithin
- acid
- esterified
- liposome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Definitions
- the present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases comprising the same.
- Liposome is a micro endoplasmic reticulum having a closed double-layered lipid membrane, in which a hydrophilic space exists. Accordingly, liposome is characterized in containing water-soluble materials in the hydrophilic inner space and capturing oil- soluble materials in the outer double-layered lipid membrane. A material which forms such liposome membrane is called as lipoid. As the lipoid, phosphoglycerides or sphingolipids are conventionally used. Lecithin or ceramide is most generally used in the field of cosmetics or foods since they have excellent moisturizing property and no toxicity to human body.
- these lecithin and ceramide are hydrophobic, and so hard to disperse in alcohol solution as well as aqueous solution.
- they have to be dispersed with heating to a high temperature of 70 "C or more, and then functional materials have to be added thereto.
- liposomizing functional compounds which are oxidized at high temperature or are thermally unstable, such as coenzyme QlO and EGF.
- thus formed liposome has disadvantages of very low stability and non-uniformity in the size.
- anionic surfactant type of phospholipidyl lipoid obtained by reacting lecithin with phosphoric acid or other polar compounds, thereby having good dispersibility to aqueous solution, is widely used.
- the lipoid is too hydrophilic, the wettability may be enhanced, but the penetration effect into skin is greatly diminished due to the difference in polarity with ingredients on skin surface.
- the lipoid is anionic salt type, it decreases the viscosity of cosmetics, thereby requiring further addition of thickening agents.
- coenzyme QlO is known as a co-enzyme promoting energy generation of cell in human body, having potent anti-oxidation power against active oxygen.
- its intake or application to skin can prevent the oxidation of cells, thereby maintaining skin elasticity and preventing the aging effectively.
- coenzyme QlO is produced in a sufficient amount up to 20 years old, but the amount decreases from the peak before or after 20 years old due to various reasons such as unbalanced diet, stress, or the like. Before or after 40 years old, the decrease is accelerated, and so supplement thereof is required.
- EGF Epidermal Growth Factor
- EGF is a protein which exists in colostrums of mother's milk, and has excellent effects in reproducing cells and promoting the recovery of wound, and so EGF is used as biological medicament for treating foot ulcer of a diabetic.
- EGF is known as an ingredient having a function of healing a wound naturally without a scar, and known to have skin reproducing effect. Accordingly, it is widely used as a raw material for functional cosmetics, as well as a medicament for healing a wound by diabetic foot ulcer, burn, cut or the like.
- Korean Patent Laid-open Publication No. 10-2005-0058635 discloses an extract from Camellia japonica having anti-inflammatory and anti-oxidation activity.
- Korean Patent Laid-open Publication No. 10-2006-0025423 discloses an extract from Viscum album L. var. coloratum having anti-inflammatory and anti-oxidation activity.
- One object of the present invention is to provide a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane.
- a solution of nanoliposome containing functional materials such as coenzyme QlO or epidermal growth factor can be prepared at low temperature, and such prepared nanoliposome has long-term stability and homogeneity, and so can be used as a raw material for composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like.
- Another object of the present invention is to provide a method for preparing a stable nanoliposome by dispersing a mixture solution of esterified lecithin and physiologically active ingredient, in nanometer size.
- the present inventors have found that if epidermal growth factor is prepared as nanoliposome and formulated with natural extract having anti-inflammatory activity, the stability is enhanced, and penetration of EGF into skin are promoted, whereby a composition having excellent healing effect to skin diseases can be obtained.
- another object of the present invention is to provide a composition for preventing or treating skin diseases, comprising nanoliposome in which epidermal growth factor is included, and one or more natural extracts having anti-inflammatory activity.
- Figure 1 is a graph representing UV/Visible absorbance (%) of the solution of nanoliposome having double layered membrane of EGF/coenzyme QlO, which is prepared by using esterified lecithin according to the present invention.
- Figure 2 is a graph representing UV/Visible transmittance (%) of the solution of nanoliposome having double layered membrane of EGF/coenzyme QlO, which is prepared by using esterified lecithin according to the present invention.
- Figure 3 is a graph representing particle size distribution of nanoliposome having double layered membrane of EGF/coenzyme QlO, which is prepared by using esterified lecithin according to the present invention.
- Figure 4 is to show the treatment effect of the present composition comprising nanoliposome when the composition is administered to a patient of mouth cancer, and a patient of laryngeal cancer, who have dermatitis caused by radiation treatment.
- One aspect of the present invention provides a nanoliposome comprising a liposome membrane containing esterif ⁇ ed lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane.
- Another aspect of the present invention provides a method for preparing a nanoliposome comprising: the 1 st step of preparing esterified lecithin by reacting lecithin with organic acid; the 2 nd step of dissolving the esterified lecithin and one or more physiologically active ingredients in a solvent; and the 3 rd step of dispersing the resultant solution to obtain liposome in nanometer size.
- compositions for preventing or treating skin diseases comprising nanoliposome which comprises a liposome membrane containing esterified lecithin, and epidermal growth factor included in inner space of the liposome membrane; and one or more natural extracts having anti-inflammatory activity.
- inclusion refers to contain (contained or containing) of water-soluble material (e.g., epidermal growth factor, ascorbic acid, etc.) in the hydrophilic space in center of the liposome, or capture (captured or capturing) of oil-soluble material (e.g., coenzyme QlO, retinol, retinyl palmitate, ascorbyl palmitate, etc.) by double-layered lipid membrane of the liposome.
- water-soluble material e.g., epidermal growth factor, ascorbic acid, etc.
- oil-soluble material e.g., coenzyme QlO, retinol, retinyl palmitate, ascorbyl palmitate, etc.
- nanoma refers to a liposome with a diameter of about 100 to 200 nm, conventionally prepared by dispersing liposome in micrometer size under pressure condition of about 1000 psi or more.
- the membrane of liposome comprises esterified lecithin.
- the membrane of liposome may comprise liposome membrane components (i.e. lipoid) which is used conventionally in liposome preparation, if necessary.
- the lipoid comprises phosphoglycerides or sphingolipids, for example, phosphatidylcholine (i.e., lecithin), hydrogenated lecithin, phosphatidylethanolamine, phosphatidylinositol, ceramide, cerebrosides (i.e., galactosyl ceramide), sphingomyelin, gangliosides, or the like.
- the lipoid also can give moisturizing effect.
- hydrogenated lecithin and/or ceramide can be preferably used.
- the hydrogenated lecithin refers to a lecithin consisting of saturated hydrocarbon which is obtained by the reduction of all unsaturated hydrocarbon in lecithin.
- the esterified lecithin contained in the membrane of liposome is dispersed well in water or alcohol, and has both hydrophilicity and hydrophobicity. Accordingly, the esterified lecithin has polarity enough to be dispersed in aqueous solvent, but not enough to be dissolved completely in the aqueous solvent.
- a stable liposome solution can be prepared even at low temperature such as 20 ° C to 60 ° C .
- the esterified lecithin can be prepared by reacting lecithin or hydrogenated lecithin with an organic acid.
- the esterif ⁇ cation process is a condensation reaction wherein the alcoholic group of the lecithin reacts with organic acid, and the resultant water molecule is eliminated therefrom.
- esterified lecithin reacts with water in aqueous solution, and is dissociated again into lecithin (alcoholic group) and a form of organic acid. Therefore, in this reaction, the esterified lecithin, lecithin (or hydrogenated lecithin) and organic acid co-exist, with maintaining proper equilibrium between esterification and dissociation according to acidity, as follows:
- the organic acid used in the preparation of the esterified lecithin comprises organic acids conventionally used in cosmetics and foods such as acetic acid, malic acid, lactic acid, glycolic acid, citric acid or oxalic acid, preferably anhydrous organic acids, and more preferably anhydrous malic acid or anhydrous acetic acid. If anhydrous acetic acid is used, the esterified lecithin shows greater hydrophilicity than the case of using anhydrous malic acid.
- the organic acid can be selected appropriately, depending on the relative amounts of hydrophilic or hydrophobic functional material to be added, or the degree of polarity of functional material. These organic acids also may exhibit an effect of removing keratinous substance or an effect of skin-softening, if applied to skin.
- the esterified lecithin can be used in an amount enough to form liposome, without special limitation, preferably in 1 to 5 parts by weight, based on 1 part by weight of physiologically active ingredient.
- the physiologically active ingredient included in inner space of the liposome membrane of the present invention may be, but not limited to, water-soluble drug, oil-soluble drug, thermally unstable functional material or the like.
- the physiologically active ingredient is one or more selected from the group consisting of coenzyme QlO and epidermal growth factor.
- the nanoliposome of the present invention may further comprise one or more selected from the group consisting of triglyceride type organic compound, preferably caprylic/capric triglyceride; anionic surfactant, preferably diethylamine cetylphosphate, ascorbyl phosphate sodium, phosphotidylcholine or triethylamine coconyl glutamine sodium; hydrogenated saturated hydrocarbon lecithin; softening agent, preferably butylated hydroxy toluene, betaine type amphiphilic surfactant preferably such as laurylamine propyl betaine, laurylbetaine, laurylaminebetaine or cocamido propylbetaine; and chelating agent, preferably sodium salt of ethyl enediaminetetraacetate.
- anionic surfactant preferably diethylamine cetylphosphate, ascorbyl phosphate sodium, phosphotidylcholine or triethylamine coconyl glutamine sodium
- the present invention also relates to a method for preparing a nanoliposome comprising: the 1 st step of preparing esterified lecithin by reacting lecithin with organic acid; the 2 nd step of dissolving the esterified lecithin, and one or more physiologically active ingredients in a solvent; and the 3 rd step of dispersing the resultant solution to obtain liposome in nanometer size.
- the esterified lecithin is prepared by condensation-reaction of lecithin with an organic acid.
- the organic acid is preferably selected from the group consisting of acetic acid, malic acid, lactic acid, glycolic acid, citric acid and oxalic acid, and anhydrides thereof.
- the physiologically active ingredient is preferably, but not limited to, water-soluble drug, oil-soluble drug, or thermally unstable functional material. More preferably, the physiologically active ingredient is one or more selected from the group consisting of coenzyme QlO and epidermal growth factor. Also, if required, as physiologically active ingredient, anti-oxidant such as coenzyme QlO, retinol, retinal, retinyl palmitate, retinoic acid, ascorbic acid, ascorbyl phosphate or salts thereof, or ascorbyl palmitate may be further used.
- anti-oxidant such as coenzyme QlO, retinol, retinal, retinyl palmitate, retinoic acid, ascorbic acid, ascorbyl phosphate or salts thereof, or ascorbyl palmitate may be further used.
- the 2 nd step preferably comprises the steps of: preparing oil-phase solution by dissolving esterified lecithin and hydrophobic active ingredient such as coenzyme QlO in organic solvent; preparing aqueous phase solution by dissolving
- ⁇ 2 hydrophilic active ingredient such as EGF in aqueous solvent
- esterified lecithin and hydrophobic active ingredient such as coenzyme QlO are dissolved in organic solvent such as ethanol.
- hydrogenated saturated hydrocarbon lecithin triglyceride type hydrophilic organic compound such as caprylic/capric triglyceride
- anionic surfactant such as diethylamine cetylphosphate, ascorbyl phosphate sodium, phosphotidylcholine or triethylamine coconyl glutamine sodium
- softening agent such as butylated hydroxy toluene
- the aqueous phase solution is prepared by dissolving hydrophilic active ingredient such as EGF in pure water.
- hydrophilic active ingredient such as EGF
- anionic surfactant such as diethylamine cetylphosphate, ascorbyl phosphate sodium, phosphotidylcholine or triethylamine coconyl glutamine sodium; or chelating agent such as sodium salt of ethylenediaminetetraacetate may be further added to the aqueous phase solution.
- the dissolution procedure of the esterif ⁇ ed lecithin and physiologically active ingredient in solvent is preferably conducted at the temperature of 20 ° C to 60 ° C .
- the temperature is lower than 20 ° C, dissolution may be conducted, but the dissolution time is long, and there may be a stability problem after the dissolution.
- the temperature is higher than 60 ° C, coenzyme QlO and/or EGF or the like as the physiologically active ingredient may be unstable.
- the mixture is homogenized by using homomixer agitator. At this time, the liposome in the homogenized liposome solution exhibits a particle size of micrometer scale.
- nanoliposome solution is obtained by passing the homogeneously mixed solution of the 2 nd step through micro fluidizer (M/F) under a pressure of 1000 psi or more, one or more times, and dispersing it to nanometer-sized liposome. If the pressure is lower than 1000 psi, it may be hard to form nanometer- sized liposome.
- M/F microfluidizer
- the homogeneously mixed solution is passed through microfluidizer (M/F) two or more times.
- the liposome contained in the nanoliposome solution as prepared above forms a double liposome of aqueous phase/oil phase, in aqueous solution, and thus can also stabilize functional material of aqueous phase existing innermost, such as EGF and optional water- soluble anti-oxidant, and can further stabilize hydrophilic active ingredients such as EGF, and hydrophobic active ingredients such as coenzyme QlO at the same time.
- the present nanoliposome containing coenzyme QlO and EGF with using esterified lecithin can be used in preparing a composition for skin such as cosmetics, medicaments for treating skin diseases, or the like by conventional methods.
- the present invention provides a composition for preventing or treating skin diseases, comprising nanoliposome which comprises a liposome membrane containing esterified lecithin, and epidermal growth factor included in inner space of the liposome membrane; and one or more natural extracts having anti- inflammatory activity.
- the present composition uses epidermal growth factor in forms of inclusion in nanoliposome, by which the pharmaceutical stability of drug and the penetration into skin can be enhanced. Also, the esterified lecithin used in preparing liposome can provide additional moisturizing effect which is advantageous in treating skin diseases.
- esterified lecithin providing moisturizing effect to wounded region can exhibit better effect for treating skin diseases.
- esterified lecithin provides effects of softening skin and stimulating skin-penetration, thereby enhancing the penetration of epidermal growth factor and natural extract into skin.
- the present composition comprises nanoliposome prepared by containing esterified lecithin in liposome membrane, the conventional problems of heating and dispersing active ingredients at high temperature (70 ° C or more), low stability, uniformity, or the like can be solved.
- the epidermal growth factor may be used in a sufficient amount to treat skin diseases, and the effective amount for treatment may be varied depending on the patient's condition, age, gender, susceptibility or the like.
- the content of the epidermal growth factor in the present composition may be 1 to 50 wt%, based on total weight of the nanoliposome.
- the nanoliposome including EGF may further comprise antioxidant.
- the anti-oxidant may comprise, but not limited to, coenzyme QlO, retinol, retinal, retinyl palmitate, retinoic acid, ascorbic acid, ascorbyl phosphate or salts thereof, or ascorbyl palmitate.
- Coenzyme QlO plays a role of co-enzyme to promote energy generation of cell in human body, and has potent anti-oxidation power against active oxygen, and so its intake or application to skin is known to be effective for preventing the oxidation of cells, thereby maintaining skin elasticity and preventing the aging effectively.
- the amount of the anti-oxidant in the present composition may be 0.1 to 10 wt%, based on total weight of the nanoliposome.
- the natural extract having anti-inflammatory activity comprises an extract from natural products which is known as containing anti-inflammatory ingredient, without limitation.
- the natural extract having anti-inflammatory activity useful for the present composition may comprise an extract from one or more natural products such as Camellia japonica, Viscum album L. var. coloratum, Ulmi cortex, Lillium brownii F. E., Pimellia ternata Thunb Breit, Bletilla striata Reichb.
- the natural extract may be used alone or in combination with two or more extracts.
- the natural extract is from Camellia japonica and/or Viscum album L.
- the natural extract may be used in various amounts depending on natural products used, extraction method, or the like. Conventionally, the content of the natural extract in the present composition may be 0.01 to 10 wt%, based on total weight of the composition.
- the present composition for preventing or treating skin diseases may be prepared by formulating the nanoliposome which is prepared as described above to comprise a liposome membrane containing esterified lecithin, and epidermal growth factor included in inner space of the liposome membrane, with the natural extract having antiinflammatory activity.
- the formulation may be conducted by dispersing and/or dissolving the natural extract having anti-inflammatory activity in the nanoliposome solution as obtained above.
- the dispersion and/or dissolution are preferably conducted at room temperature.
- the present composition may further comprise a stabilizing agent such as amino acid, sodium bisulfite, sodium metabisulfite, sodium sulfite, ethylendiaminetetraacetate disodium, sodium bisulfide, sodium formaldehyde sulfoxylate, thiourea, acetone sodium bisulfite or the like; a moisturizing agent such as ceramide, glycerin, propylene glycol, ammonium alginate, cyclomethicone, dimethicone, polydextrose, sodium hyaluronate, sodium lactate, solbitol, triacetin, triethanolamine, xylitol or the like; an emulsifying agent such as polyoxyethylene alkylether, polyoxyethylene castor oil derivative, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene stearate or the like; or a pharmaceutically acceptable additive such as sodium benzoate, methyl paraoxybenzoate, ethyl
- the present composition may be prepared in various forms of cosmetics such as skin lotion, nutritional lotion, nutritional cream, massage cream, nutritional essence, pack, make-up base, foundation, body oil, hair oil, shampoo, rinse, etc.
- Nanoliposome solution was prepared by passing the obtained homogeneous mixture through micro fluidizer under the pressure of more than 1000 psi one or more times to disperse the liposome in nanometer size. The temperature condition of the passing procedure was cooled to below room temperature by using cooling water.
- a nanoliposome solution was prepared by the same method as Example 3, except for using 2.4g of EGF.
- a nanoliposome solution was prepared by the same method as Example 3, except for using 30g of esterified lecithin.
- a nanoliposome solution was prepared by the same method as Example 3, except for using 1Og of lauryl betaine (betaine type amphiphilic surfactant) instead of diethylamine cetylphosphate (anionic surfactant).
- lauryl betaine betaine type amphiphilic surfactant
- diethylamine cetylphosphate anionic surfactant
- a nanoliposome solution was prepared by the same method as Example 3, except for using 5Og of esterified lecithin, and not using hydrogenated saturated hydrocarbon lecithin nor diethylamine cetylphosphate.
- Example 8 According to the same method as Example 3, an aqueous phase solution was prepared, thus prepared aqueous phase solution was mixed with the oil-phase solution as prepared above, and the mixture was dispersed in nanometer size to prepare nanoliposome solution.
- a nanoliposome solution was prepared by the same method as Example 7, except for using 3Og of esterified lecithin, and not using hydrogenated saturated hydrocarbon lecithin.
- a nanoliposome solution was prepared by the same method as Example 7, except for using 1Og of lauryl betaine (betaine type amphiphilic surfactant) instead of diethylamine cetylphosphate.
- lauryl betaine betaine type amphiphilic surfactant
- a nanoliposome solution was prepared by the same method as Example 7, except for using 5Og of esterified lecithin, and not using hydrogenated saturated hydrocarbon lecithin nor diethylamine cetylphosphate.
- Example 11 1) 15g of esterified lecithin, 15g of hydrogenated saturated hydrocarbon lecithin, 20Og of caprylic/capric triglyceride (MCT), 0.5g of butylated hydroxy toluene (BHT) and 1Og of coenzyme QlO were added to HOg of ethanol, and the mixture was heated to about 50 ° C , stirred and dissolved. The dissolved mixture was then cooled to room temperature. 2) 2.4g of EGF was dissolved in 1Og of distilled water. Thus obtained solution was added to the solution prepared in the above step 1).
- a nanoliposome solution was prepared by the same method as Example 11 , except for using 35g of esterified lecithin, and not using hydrogenated saturated hydrocarbon lecithin.
- a nanoliposome solution was prepared by the same method as Example 11, except for using 50g of esterified lecithin, and not using hydrogenated saturated hydrocarbon
- Example 15 A nanoliposome solution was prepared by the same method as Example 14, except for using Ig of ascorbyl phosphate sodium instead of diethylamine cetylphosphate.
- a nanoliposome solution was prepared by the same method as Example 14, except for using Ig of triethylamine coconyl glutamine sodium (MIAMI CT130, anionic surfactant) instead of diethylamine cetylphosphate.
- MIAMI CT130 anionic surfactant
- a nanoliposome solution was prepared by the same method as Example 14, except for using 1 g of laurylamine propyl betaine (betaine type amphiphilic surfactant) instead of diethylamine cetylphosphate.
- a nanoliposome solution was prepared by the same method as Example 7, except for using 3Og of hydrogenated saturated hydrocarbon lecithin, and not using esterified lecithin. Preparation of formulation for external use
- Example 19 5ml of the nanoliposome solution prepared in Example 3 was added to 95g of nutritional lotion base containing Camellia japonica extract which was prepared according to the example 2 of Korean Laid-open Publication No. 10-2005-0058635. Then, the mixture was stirred at room temperature for 20 minutes to obtain a composition for preventing or treating skin diseases.
- Example 19 5ml of the nanoliposome solution prepared in Example 3 was added to 95g of nutritional lotion base containing Viscum album L. var. coloratum extract which was prepared according to the formulation example 1 of Korean Laid-open Publication No. 10-2006- 0025423. Then, the mixture was stirred at room temperature for 20 minutes to obtain a composition for preventing or treating skin diseases.
- Example 8 For the nanoliposome solutions prepared in the above Example 8 (using esterif ⁇ ed lecithin only), Example 7 (using esterif ⁇ ed lecithin and hydrogenated saturated hydrocarbon lecithin) and Comparative Example (using hydrogenated saturated hydrocarbon lecithin only), the average particle size and gelation due to long-term storage at room temperature were compared. The results are shown in the following Table 1. Also, observation was conducted to confirm occurrence of the Ostwald ripening, which is a mechanism of particle growth by depositing substances on bigger particles due to particle size difference between particles in solution [Ostwald, Z Phys. Chem. (34), 1900, 495-5031].
- the time to gelate was determined by the time for which the gelated solution was not re-dispersed nor re-dissolved in spite of re-stirring.
- Test temperature room temperature (20 ° C in average)
- the visible light in 400 nm to 700 nra region was not scattered nor absorbed substantially, which means that the prepared nanoliposome solution was very clear, and the size of liposome was uniform.
- Example 8 the particle size distribution was measured. The result is shown in Figure 3.
- the nanoliposome particles were distributed within a narrow range, which means that the prepared nanoliposome solution was very clear, and the size of liposome was uniform.
- Example 18 (59.4Gy) and thus had a severe inflammation on the skin after the radiation treatments (the left column of Figure 4), the composition prepared in Example 18 was applied to
- Example 18 For two laryngeal cancer patients who had a severe inflammation on the skin, the composition prepared in Example 18 was applied to cover the diseased part thoroughly, 2 times per day for about 1 month (2006. 3. 29 ⁇ 2006. 4. 17) and for about 1 week (2006. 4. 11 ⁇ 2006. 4. 18). During the administration period, the diseased part had been observed everyday. After about 1 month and about 1 week, respectively, the diseased part was recovered to nearly normal skin (Figure 4).
- the nanoliposome according to the present invention forms a liposome membrane containing esterified lecithin, and so can liposomize thermally unstable functional materials safely at low temperature and capture both the hydrophilic materials and hydrophobic materials simultaneously. Also, since anhydrous organic acid for removing keratinous substance is used as functional group, it is advantageous to exhibit various functional effects such as removing keratinous substance or skin-softening.
- the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability.
- the esterified lecithin used in preparing liposome can provide additional moisturizing effect which is advantageous in treating skin diseases.
- skin diseases are caused from wound by burn, cut or the like, or radiation treatment to cancer patient.
- the esterified lecithin providing moisturizing effect to wounded region can exhibit better effect for treating skin diseases. Further, the esterified lecithin provides effects of softening skin and stimulating skin-penetration, thereby enhancing the penetration of epidermal growth factor and natural extract into skin. Furthermore, since the present composition comprises nanoliposome prepared by containing esterified lecithin in liposome membrane, the conventional problems of heating and dispersing active ingredients at high temperature (70 ° C or more), low stability and uniformity, or the like can be solved.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07793354A EP2054035B1 (en) | 2006-08-02 | 2007-08-01 | Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same |
AT07793354T ATE537814T1 (en) | 2006-08-02 | 2007-08-01 | NANOLIPOSOME WITH ESTERIFIED LECITHIN AND PRODUCTION METHOD THEREOF AND COMPOSITION CONTAINING SAME FOR THE PREVENTION OR TREATMENT OF SKIN DISEASES |
CN2007800327079A CN101511340B (en) | 2006-08-02 | 2007-08-01 | Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same |
JP2009522716A JP5191988B2 (en) | 2006-08-02 | 2007-08-01 | Nanoliposomes using esterified lecithin, method for producing the same, and composition for preventing or treating skin diseases comprising the same |
US12/375,739 US8685440B2 (en) | 2006-08-02 | 2007-08-01 | Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2006-0072809 | 2006-08-02 | ||
KR1020060072809A KR100752990B1 (en) | 2006-08-02 | 2006-08-02 | Compositions for preventing or treating skin diseases comprising nanoliposomes and natural extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008016258A1 true WO2008016258A1 (en) | 2008-02-07 |
Family
ID=38615652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/003699 WO2008016258A1 (en) | 2006-08-02 | 2007-08-01 | Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same |
Country Status (9)
Country | Link |
---|---|
US (1) | US8685440B2 (en) |
EP (1) | EP2054035B1 (en) |
JP (1) | JP5191988B2 (en) |
KR (1) | KR100752990B1 (en) |
CN (1) | CN101511340B (en) |
AT (1) | ATE537814T1 (en) |
RU (1) | RU2418575C2 (en) |
TW (1) | TWI325325B (en) |
WO (1) | WO2008016258A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2325901A1 (en) * | 2008-02-20 | 2009-09-23 | Heber Farma Sl | Vehiculization of the epidermic growth factor through biomembranes. (Machine-translation by Google Translate, not legally binding) |
CN106963975A (en) * | 2017-03-08 | 2017-07-21 | 广州欧化药业有限公司 | Bletilla glucomannan self-assembling nano particles and its preparation method and application |
US10016389B2 (en) | 2011-01-05 | 2018-07-10 | Livon Laboratories | Method of making liposomes, liposome compositions made by the methods, and methods of using the same |
WO2019075801A1 (en) * | 2017-10-19 | 2019-04-25 | 广州无添加主义化妆品有限公司 | Skincare mask and preparation method therefor |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100824958B1 (en) | 2006-12-05 | 2008-04-28 | 주식회사 피코스텍 | Cosmetic composition containing oriental herb extract and nano ceramide |
KR101290790B1 (en) | 2011-06-22 | 2013-07-30 | 제이앤씨화장품 주식회사 | Skin trouble improvement and calming care composition containing oriental medicine nanosome |
KR101421171B1 (en) * | 2011-08-31 | 2014-07-22 | 재단법인 제이씨비 공동생물과학연구소 | Compositions for Improving Skin Conditions Comprising Extracellular Domain of Human Bone Morphogenetic Protein Receptor 1a as Active Ingredient |
RU2482867C1 (en) * | 2012-03-20 | 2013-05-27 | Федеральное государственное бюджетное учреждение "Научный центр неврологии" Российской академии медицинских наук (ФГБУ "НЦН" РАМН) | Use of l-carnosine for producing nanopreparation possessing antihypoxic and antioxidant activity |
JP6000033B2 (en) * | 2012-09-18 | 2016-09-28 | 株式会社ピカソ美化学研究所 | Liposomes imparting heat resistance to encapsulated substance and method for producing the same |
CA2851130C (en) * | 2012-11-22 | 2019-10-01 | Chia-Hung Chen | A pharmaceutical composition used for reducing damage caused by free radicals |
CN104127326B (en) * | 2014-07-10 | 2017-01-11 | 上海应用技术学院 | Nano solid lipid carrier covering Vc palmitate and preparation method thereof |
WO2016108634A2 (en) | 2014-12-30 | 2016-07-07 | (주)셀트리온 | Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same |
EP3437488B8 (en) * | 2016-03-30 | 2021-03-17 | Riken Vitamin Co., Ltd. | Carotenoid-containing particles |
CN108309939B (en) * | 2018-03-23 | 2020-06-05 | 中国中医科学院中药研究所 | Nano-structure lipid carrier containing schisandra lignan compounds and preparation method and determination method thereof |
CN108283603A (en) * | 2018-04-02 | 2018-07-17 | 吴伟华 | A kind of preparation method of labour protection cold cream |
RU2740553C2 (en) * | 2019-01-30 | 2021-01-15 | Анастасия Андреевна Карбаинова | Method of producing liposomal form of betulin, having hepatoprotective activity |
CN111803396A (en) * | 2020-06-30 | 2020-10-23 | 黑龙江省医院 | Cosmetic composition based on retinaldehyde and glycylglycine oleamide and preparation method thereof |
CN113143811B (en) * | 2020-12-14 | 2023-01-24 | 洛阳师范学院 | Preparation method of peony extract compound liposome |
CN112494351A (en) * | 2020-12-21 | 2021-03-16 | 上海毕图生物科技有限公司 | Preparation method of antioxidant essence acting on skin cells |
CN113876713B (en) * | 2021-11-23 | 2023-02-03 | 河南省儿童医院郑州儿童医院 | Amoxicillin sodium and clavulanate potassium liposome and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4944948A (en) * | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
WO1990011781A1 (en) * | 1989-04-04 | 1990-10-18 | Alcon Laboratories, Inc. | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
JPH0348614A (en) * | 1989-07-17 | 1991-03-01 | Wakunaga Pharmaceut Co Ltd | Epithelial cell growth factor-bound liposome |
US5310958A (en) * | 1989-07-06 | 1994-05-10 | Yutaka Mizushima | Lysolecithin derivatives |
KR100768151B1 (en) * | 2006-04-10 | 2007-10-17 | 주식회사 대웅 | Nanoliposome using esterified lecithin |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
FR2714602B1 (en) * | 1993-12-30 | 1996-02-09 | Oreal | Anti-acne composition for the simultaneous treatment of the superficial and deep layers of the skin, its use. |
EP0892638B1 (en) | 1996-04-04 | 2002-11-13 | Cilag AG | Liposome-based topical vitamin d formulation |
IT1291278B1 (en) * | 1996-07-05 | 1999-01-07 | Errekappa Euroterapici S P A | NIMESULIDE-BASED PHARMACEUTICAL PREPARATION FOR TOPICAL USE |
KR100366439B1 (en) * | 2000-02-21 | 2003-01-09 | 주식회사 대웅 | Stable Pharmaceutical Composition Comprising Epidermal Growth Factor as an Active Ingredient |
WO2004100998A2 (en) * | 2003-05-07 | 2004-11-25 | General Electric Company | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
KR20040101709A (en) * | 2003-05-26 | 2004-12-03 | 나드리화장품주식회사 | Cosmetic composition containing camellia japonica extract stabilized with nanoliposome |
KR20050040595A (en) * | 2003-10-29 | 2005-05-03 | 주식회사 엘지생활건강 | Skin anti-aging cosmetic composition |
FR2862306B1 (en) * | 2003-11-17 | 2008-05-30 | Aventis Pasteur | VACCINE COMPOSITION |
KR100530880B1 (en) * | 2003-12-05 | 2005-11-23 | 한국콜마 주식회사 | The cosmetic products of phospholipid liposome with nano-particle size and its manufacturing method |
KR100556524B1 (en) | 2003-12-12 | 2006-03-06 | 코스맥스 주식회사 | Camellia japonica extract having anti-inflammatory and anti-oxidative activities, and cosmetic composition comprising the same |
KR100603814B1 (en) * | 2004-03-11 | 2006-07-25 | 바이오스펙트럼 주식회사 | Nano liposome composition |
KR100553160B1 (en) * | 2004-07-09 | 2006-02-22 | 한국콜마 주식회사 | Nano sized phospholipid liposome composition comprising coenzym Q10 and manufacturing method thereof |
KR100642526B1 (en) | 2004-09-16 | 2006-11-03 | 코스맥스 주식회사 | Viscum album extract having anti-inflammatory and anti-oxidative activities, and cosmetic composition comprising the same |
-
2006
- 2006-08-02 KR KR1020060072809A patent/KR100752990B1/en active IP Right Grant
-
2007
- 2007-08-01 US US12/375,739 patent/US8685440B2/en active Active
- 2007-08-01 RU RU2009107154/15A patent/RU2418575C2/en active
- 2007-08-01 WO PCT/KR2007/003699 patent/WO2008016258A1/en active Application Filing
- 2007-08-01 CN CN2007800327079A patent/CN101511340B/en active Active
- 2007-08-01 TW TW096128163A patent/TWI325325B/en active
- 2007-08-01 EP EP07793354A patent/EP2054035B1/en active Active
- 2007-08-01 JP JP2009522716A patent/JP5191988B2/en active Active
- 2007-08-01 AT AT07793354T patent/ATE537814T1/en active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4944948A (en) * | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
WO1990011781A1 (en) * | 1989-04-04 | 1990-10-18 | Alcon Laboratories, Inc. | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
US5310958A (en) * | 1989-07-06 | 1994-05-10 | Yutaka Mizushima | Lysolecithin derivatives |
JPH0348614A (en) * | 1989-07-17 | 1991-03-01 | Wakunaga Pharmaceut Co Ltd | Epithelial cell growth factor-bound liposome |
KR100768151B1 (en) * | 2006-04-10 | 2007-10-17 | 주식회사 대웅 | Nanoliposome using esterified lecithin |
Non-Patent Citations (1)
Title |
---|
OSTWALD, Z PHYS. CHEM., vol. 34, 1900, pages 495 - 5031 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2325901A1 (en) * | 2008-02-20 | 2009-09-23 | Heber Farma Sl | Vehiculization of the epidermic growth factor through biomembranes. (Machine-translation by Google Translate, not legally binding) |
US10016389B2 (en) | 2011-01-05 | 2018-07-10 | Livon Laboratories | Method of making liposomes, liposome compositions made by the methods, and methods of using the same |
CN106963975A (en) * | 2017-03-08 | 2017-07-21 | 广州欧化药业有限公司 | Bletilla glucomannan self-assembling nano particles and its preparation method and application |
WO2019075801A1 (en) * | 2017-10-19 | 2019-04-25 | 广州无添加主义化妆品有限公司 | Skincare mask and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
EP2054035B1 (en) | 2011-12-21 |
TWI325325B (en) | 2010-06-01 |
KR100752990B1 (en) | 2007-08-30 |
US20090263473A1 (en) | 2009-10-22 |
CN101511340B (en) | 2011-11-16 |
US8685440B2 (en) | 2014-04-01 |
EP2054035A4 (en) | 2011-03-23 |
RU2418575C2 (en) | 2011-05-20 |
EP2054035A1 (en) | 2009-05-06 |
RU2009107154A (en) | 2010-09-10 |
JP5191988B2 (en) | 2013-05-08 |
JP2009545587A (en) | 2009-12-24 |
ATE537814T1 (en) | 2012-01-15 |
CN101511340A (en) | 2009-08-19 |
TW200815021A (en) | 2008-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8685440B2 (en) | Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same | |
US11931321B2 (en) | Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same | |
CA2426885C (en) | Complexes of phosphate derivatives | |
EP2120872B1 (en) | Nanoemulsion | |
EP1513492B1 (en) | Microemulsions having a binary phase differentiability and active substance differentiability, the production thereof and their use, particularly for the topical supply of oxygen | |
EP2298282B1 (en) | Combination of drugs having different physical properties into single dosage form | |
CN1255053A (en) | Ascorbyl-phosphoryl-cholesterol | |
KR100785484B1 (en) | Base composition encapsulating high concentration of idebenone with nano sizes, its manufacturing method thereof, and cosmetic compositions containing it | |
KR101443180B1 (en) | Novel Drug Delivery System for Percutaneous Absorption, Composition for External Preparation Preventing Hair Loss, and Cosmetics Using the Same | |
KR102138733B1 (en) | Cosmetic composition for wrinkle improvement containing phospholipid nano-structure | |
KR20070023333A (en) | A cosmeticss to promote the transepidermal absorption and stabilize ursolic acid for anti-wrinkle and its manufacturing method thereof | |
KR20160150473A (en) | Cosmetic composition containing non-toxic sulfur for sikn moisture, anti-inflammatory and immune enhancement and manufacturing the same | |
KR101034567B1 (en) | Drug delivery system and compositions of preventing loss of hair and promoting growth of hair | |
JP4011594B2 (en) | Complex with enhanced stability and bioavailability and method for producing the same | |
KR100831627B1 (en) | Reverse-Phase Multi-Lamella Vesicle Capturing Aqueous Physiologically Active Ingredients | |
JP2005281174A (en) | Active oxygen eliminating agent | |
AU2002214821A1 (en) | Complexes of phosphate derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780032707.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07793354 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009522716 Country of ref document: JP Ref document number: 575/CHENP/2009 Country of ref document: IN Ref document number: 2007793354 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009107154 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12375739 Country of ref document: US |